Alembic Pharmaceuticals Ltd shares in focus as company secures USFDA final approval for Valganciclovir for Oral Solution
Why did Alembic Pharmaceuticals Ltd shares jump today?
Alembic Pharmaceuticals Ltd shares edged higher on Tuesday, with the stock trading at ₹770.95 as of 04:18 PM, reflecting a gain of 0.5%. The uptick in share price came after the company announced a significant regulatory milestone — it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Valganciclovir for Oral Solution, 50 mg/mL. This approval marks a key win for the Vadodara-based pharmaceutical company as it continues to expand its presence in the highly competitive US generics market.
Valganciclovir is an important antiviral medication used to prevent and treat cytomegalovirus (CMV) infections, particularly in patients who have undergone organ transplants or those with weakened immune systems. The USFDA final approval means Alembic can now commercially launch this product in the United States, giving the company access to yet another product in its growing portfolio of approved generics. The oral solution formulation at 50 mg/mL is especially relevant for patients who have difficulty swallowing tablets, including pediatric and immunocompromised individuals.
The announcement was made through formal filings to both the BSE and NSE on 27th October, with Company Secretary Chirag K. Shukla communicating the development to the stock exchanges. While the share price movement was modest at 0.5%, the approval adds to Alembic's track record of securing US regulatory clearances and strengthens its revenue pipeline from the US market. Investors and analysts will be watching closely to see how the company capitalises on this approval in the coming quarters as it rolls out the product and captures market share in this therapeutic segment.
What does Alembic Pharmaceuticals Ltd do?
Alembic Pharmaceuticals Limited is a pharmaceutical company headquartered in Vadodara, India, with its registered office on Alembic Road. The company is publicly listed, trading on the Bombay Stock Exchange under Scrip Code 533573 and on the National Stock Exchange under the symbol APLLTD. Alembic Pharmaceuticals develops and manufactures pharmaceutical products and works to secure regulatory approvals across major markets. The company maintains corporate operations from its Vadodara base and engages with stock exchanges to keep shareholders informed of key developments.
One of the company's core activities is developing and securing approvals for pharmaceutical formulations, including oral solutions. For instance, Alembic Pharmaceuticals received a US Food & Drug Administration (USFDA) Final Approval for Valganciclovir for Oral Solution, 50 mg/mL, demonstrating its engagement with the U.S. regulatory process and its ability to bring pharmaceutical products through to final approval in the United States market. The company operates under the Corporate Identification Number L24230GJ2010PLC061123 and maintains an active presence through its official website and corporate communications.
Alembic Pharmaceuticals Ltd Financials
In CroresAlembic Pharmaceuticals Ltd recorded revenue of ₹1,847.72 crores in March 2026, which grew to ₹2,149.77 crores in June 2026, representing a sequential increase of approximately 16.3% or around ₹302 crores, indicating a healthy top-line expansion during the quarter. However, despite the strong revenue growth, the company's profit moved in the opposite direction — declining from ₹202.70 crores in March 2026 to ₹173.07 crores in June 2026, a sequential drop of approximately 14.6% or about ₹29.63 crores. This divergence between rising revenue and falling profitability suggests that higher costs — possibly due to increased raw material expenses, operating costs, or other margin pressures — offset the gains from improved sales. The trend indicates that while demand and top-line performance are growing, profitability per rupee of revenue has come under pressure in the June 2026 quarter.
Alembic Pharmaceuticals Ltd Shareholding Pattern
Promoter holding stands at 69.87% of the total share capital. Foreign Institutional Investors (FIIs) hold 4.55% stake in the company, while Domestic Institutional Investors (DIIs) hold 15.44%. Public shareholders hold the remaining 10.16% stake in Alembic Pharmaceuticals Ltd.
Alembic Pharmaceuticals Ltd FAQs
Q: Why did Alembic shares jump 0.5% today?
Alembic Pharmaceuticals Limited receives USFDA Final Approval for Valganciclovir for Oral Solution, 50 mg/mL.. This corporate action caught investor attention, leading to increased trading activity in the stock.
Q: What is the shareholding pattern of Alembic Pharmaceuticals Ltd?
As per the latest data, promoters hold 69.87% stake in Alembic Pharmaceuticals Ltd, while FII holding stands at 4.55%. Domestic institutional investors hold 15.44%, and public shareholders account for 10.16% of the equity.
Q: What is the current stock price of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd shares are currently trading at ₹770.95, recording a gain of 0.5% from the previous close.
Q: What is the market capitalization of Alembic Pharmaceuticals Ltd?
The company currently has a market capitalization of ₹15154.03 crore, reflecting its valuation in the Indian equity market.